Benitec Biopharma Inc. (NASDAQ:BNTC) Director Suvretta Capital Management, L Acquires 27,502 Shares of Stock

Benitec Biopharma Inc. (NASDAQ:BNTC) Director Suvretta Capital Management, L bought 27,502 shares of Benitec Biopharma stock in a transaction dated Monday, December 23rd. The stock was acquired at an average cost of $10.98 per share, with a total value of $301,971.96. Following the completion of the acquisition, the director now owns 7,981,725 shares of the company’s stock, valued at $87,639,340.50. This represents a 0.35 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Suvretta Capital Management, L also recently made the following trade(s):

• On Tuesday, December 3rd, Suvretta Capital Management, L acquired 42,000 shares of Benitec Biopharma stock. The stock was acquired at an average cost of $9.60 per share, for a total transaction of $403,200.00.

Benitec Biopharma Stock Performance

Shares of BNTC opened at $12.00 on Friday. Benitec Biopharma Inc. has a 52-week low of $2.69 and a 52-week high of $13.29. The stock’s 50-day simple moving average is $10.89 and its 200 day simple moving average is $9.54. The stock has a market capitalization of $278.59 million, a price-to-earnings ratio of -4.23 and a beta of 0.89.

Analysts Set New Price Targets

BNTC has been the topic of a number of research analyst reports. Guggenheim reissued a “buy” rating and issued a $17.00 price target on shares of Benitec Biopharma in a report on Tuesday, December 3rd. Baird R W raised shares of Benitec Biopharma to a “strong-buy” rating in a report on Thursday, December 12th. JMP Securities increased their price objective on Benitec Biopharma from $16.00 to $18.00 and gave the company a “market outperform” rating in a report on Monday, October 14th. Piper Sandler restated an “overweight” rating on shares of Benitec Biopharma in a research note on Friday, October 18th. Finally, Oppenheimer initiated coverage on Benitec Biopharma in a research note on Wednesday, October 16th. They set an “outperform” rating and a $35.00 price target for the company. Seven analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Benitec Biopharma has an average rating of “Buy” and an average target price of $24.43.

Institutional Investors Weigh In On Benitec Biopharma

A number of institutional investors and hedge funds have recently modified their holdings of the company. GAMMA Investing LLC grew its stake in Benitec Biopharma by 20.3% during the third quarter. GAMMA Investing LLC now owns 6,540 shares of the biotechnology company’s stock valued at $60,000 after acquiring an additional 1,102 shares in the last quarter. Acuta Capital Partners LLC bought a new position in Benitec Biopharma in the 3rd quarter valued at $274,000. Simplify Asset Management Inc. purchased a new position in shares of Benitec Biopharma during the 2nd quarter valued at $358,000. Geode Capital Management LLC increased its holdings in shares of Benitec Biopharma by 31.3% in the third quarter. Geode Capital Management LLC now owns 83,987 shares of the biotechnology company’s stock worth $772,000 after purchasing an additional 20,012 shares during the period. Finally, Nantahala Capital Management LLC purchased a new stake in shares of Benitec Biopharma in the second quarter worth $5,881,000. 52.19% of the stock is owned by hedge funds and other institutional investors.

About Benitec Biopharma

Benitec Biopharma Inc, a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy.